DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-755/S-015

GlaxoSmithKline
Attention: Deneen Stewart, Ph.D.
Associate Director, U.S. Regulatory Affairs
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101-7929

Dear Dr. Stewart:

Please refer to your supplemental new drug application dated February 19, 2007, received February 20, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for AUGMENTIN ES-600® (amoxicillin/clavulanate potassium) Powder for Oral Suspension.

This application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

This "Changes Being Effected" supplemental new drug application provides for revisions to the **WARNINGS** and **PRECAUTIONS/Information for Patients** sections to include information on *Clostridium difficile* associated disease (CDAD).

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format submitted on February 19, 2007.

We note that your February 19, 2007 submission includes final printed labeling (FPL) for your package insert. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kathrine Laessig
4/17/2008 12:49:06 PM